Colorectal CancerPhase 3NCT01011478
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery
A Phase 3 study testing rosuvastatin in people with Colorectal Cancer and Precancerous Condition, run by NSABP Foundation Inc at 587 sites in 2 countries.
Trial summary
RATIONALE: Rosuvastatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving rosuvastatin after surgery may kill any tumor cells that remain after surgery. It may also keep polyps from forming or colon cancer from coming back. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Colorectal Cancer, Precancerous Condition
- What is being tested?
- rosuvastatin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 406 participants
- Where
- 587 sitesin 2 countries
- Study dates
- Mar 2010to Feb 2015
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Patients must have the ability to swallow oral medication.
- Patients must have resected adenocarcinoma of the colon staged as American Joint Committee on Cancer (AJCC) Stage 0, I, II, or III.
- Patients must have had surgical resection of the colon adenocarcinoma with curative intent within 1 year prior to randomization. (Laparoscopically-assisted colectomy is permitted.)
- Patients must have completed any adjuvant therapy prior to randomization.
- Patients who are taking cardioprotective low-dose aspirin at study entry must not have clinically significant toxicity, as determined by the investigator, that precludes continuation of aspirin, and the patient must be willing to continue aspirin therapy (81 mg or 325 mg) throughout study therapy.
Show all 11Show fewer
- Colonoscopy requirements within 180 days prior to randomization:
- The patient must have either undergone a preoperative or postoperative documented colonoscopy to the cecum (or small bowel anastomosis) with adequate bowel preparation.
- All observed polyps must have been removed. (Polyps can be removed during colonoscopy or surgery performed prior to randomization.)
- Postoperative serum creatinine performed within 90 days prior to randomization must be less than or equal to 1.5 x upper limit of normal (ULN) for the lab.
- The following criteria for evidence of adequate hepatic function based on postoperative testing performed within 90 days prior to randomization must be met: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) less than or equal to 3.0 x ULN for the lab, and Total bilirubin less than or equal to 1.5 x ULN for the lab
Who cannot join
- Tumor with the distal border located less than 12 cm from the anal verge.
- Total colectomy or total proctocolectomy.
- Classic Familial Adenomatous Polyposis, Attenuated Familial Adenomatous Polyposis (i.e., 20 or more adenomas, either synchronous or metachronous), or Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome).
- Malabsorption syndrome, ulcerative colitis, inflammatory bowel disease, resection of the stomach or small bowel, or other disease significantly affecting gastrointestinal function.
- History of documented upper GI bleeding or upper GI ulcerative disease.
- Statin use within 30 days prior to randomization.
Show all 17Show fewer
- Hyperlipidemia with clinical indication for statin therapy or other prescribed medication. Determination of acceptable fasting lipid values, within 90 days prior to randomization, should be in accordance with current dyslipidemia management guidelines.
- Unwillingness to discontinue chronic use of nonsteroidal antiinflammatory drugs (NSAIDs) (other than cardioprotective low-dose aspirin 81 mg or 325 mg) prior to randomization.
- Anticipated need for chronic use of NSAIDs (other than cardioprotective low-dose aspirin 81 mg or 325 mg).
- Inadequately treated hypothyroidism, as determined by the investigator.
- History of myopathy or rhabdomyolysis.
- Hypersensitivity or intolerance to statins.
- Chronic drug therapy with cyclosporine, coumarin anticoagulants, gemfibrozil, some other lipid-lowering therapies (fibrates or niacin), lopinavir/ritonavir, or drugs (such as ketoconazole, spironolactone, or cimetidine) that lower levels or activity of steroid hormones.
- Pregnancy or lactation at the time of study entry. (Pregnancy testing must be performed within 14 days prior to randomization according to institutional standards for women of childbearing potential.)
- Previous malignancies unless the patient has been disease-free for 5 or more years prior to randomization and is deemed by the physician to be at low risk for recurrence. Patients with the following cancers are eligible if diagnosed and treated within the past 5 years: all in situ cancers and basal cell and squamous cell carcinoma of the skin.
- Other non-malignant systemic disease that would preclude a patient from receiving rosuvastatin or would prevent prolonged follow-up.
- Administration of any investigational agent within 30 days before randomization.
Trial locations and contacts
587 sites in 2 countries.
303 sites in 2 countries
United States300 sites
Oncology Services of Aberdeen
Aberdeen, South Dakota, 57401
Rosenfeld Cancer Center at Abington Memorial Hospital
Abington, Pennsylvania, 19001
McDowell Cancer Center at Akron General Medical Center
Akron, Ohio, 44307
Summa Center for Cancer Care at Akron City Hospital
Akron, Ohio, 44309-2090
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany, Georgia, 31701
Lovelace Medical Center - Downtown
Albuquerque, New Mexico, 87102
Hematology Oncology Associates, PC
Albuquerque, New Mexico, 87106
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87131-5636
CHRISTUS Cabrini Cancer Center
Alexandria, Louisiana, 71301
Tulane Cancer Center Office of Clinical Research
Alexandria, Louisiana, 71315-3198
Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
Allentown, Pennsylvania, 18105
American Fork Hospital
American Fork, Utah, 84003
McFarland Clinic, PC
Ames, Iowa, 50010
Kaiser Permanente Medical Center - Anaheim/Orange County
Anaheim, California, 92807
AnMed Cancer Center
Anderson, South Carolina, 29621
Saint Joseph Mercy Cancer Center
Ann Arbor, Michigan, 48106-0995
CCOP - Michigan Cancer Research Consortium
Ann Arbor, Michigan, 48106
Regional Medical Center
Anniston, Alabama, 36207
Langlade Memorial Hospital
Antigo, Wisconsin, 54409
Kaiser Permanente - Deer Valley
Antioch, California, 94531
Randolph Hospital
Asheboro, North Carolina, 27203-5400
Mission Hospitals - Memorial Campus
Asheville, North Carolina, 28801
Piedmont Hospital
Atlanta, Georgia, 30309
Northside Hospital Cancer Center
Atlanta, Georgia, 30342-1611
Saint Joseph's Hospital of Atlanta
Atlanta, Georgia, 30342-1701
CCOP - Atlanta Regional
Atlanta, Georgia, 30342
MBCCOP - Medical College of Georgia Cancer Center
Augusta, Georgia, 30912
Harold Alfond Center for Cancer Care
Augusta, Maine, 04330
Aurora Presbyterian Hospital
Aurora, Colorado, 80012
Rush-Copley Cancer Care Center
Aurora, Illinois, 60504
WellStar Cobb Hospital
Austell, Georgia, 30106
Kaiser Permanente Medical Center - Baldwin Park
Baldwin Park, California, 91706
Harry and Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center
Baltimore, Maryland, 21237
Kaiser Permanente at Woodlawn Medical Center
Baltimore, Maryland, 21244
CancerCare of Maine at Eastern Maine Medical Center
Bangor, Maine, 04401
Hematology-Oncology Clinic
Baton Rouge, Louisiana, 70809
Mary Bird Perkins Cancer Center - Baton Rouge
Baton Rouge, Louisiana, 70809
Battle Creek Health System Cancer Care Center
Battle Creek, Michigan, 49017
St. Francis Hospital and Health Centers - Beech Grove Campus
Beech Grove, Indiana, 46107
Overlake Cancer Center at Overlake Hospital Medical Center
Bellevue, Washington, 98004
Kaiser Permanente Medical Center - Bellflower
Bellflower, California, 90706
St. Joseph Cancer Center
Bellingham, Washington, 98225
Lehigh Valley Hospital - Muhlenberg
Bethlehem, Pennsylvania, 18017
Hematology Oncology Associates of the Quad Cities
Bettendorf, Iowa, 52722
Study site
Bettendorf, Iowa, 52722
Mecosta County Medical Center
Big Rapids, Michigan, 49307
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
St. Vincent Healthcare Cancer Care Services
Billings, Montana, 59101
Hematology-Oncology Centers of the Northern Rockies - Billings
Billings, Montana, 59102
Billings Clinic - Downtown
Billings, Montana, 59107-7000
Medcenter One Hospital Cancer Care Center
Bismarck, North Dakota, 58501
Mid Dakota Clinic, PC
Bismarck, North Dakota, 58501
St. Alexius Medical Center Cancer Center
Bismarck, North Dakota, 58502
Illinois CancerCare - Bloomington
Bloomington, Illinois, 61701
St. Joseph Medical Center
Bloomington, Illinois, 61701
Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
Boise, Idaho, 83706
Central Care Cancer Center at Carrie J. Babb Cancer Center
Bolivar, Missouri, 65613
Boston University Cancer Research Center
Boston, Massachusetts, 02118
Boulder Community Hospital
Boulder, Colorado, 80301-9019
Bozeman Deaconess Cancer Center
Bozeman, Montana, 59715
St. Joseph's Medical Center
Brainerd, Minnesota, 56401
Olympic Hematology and Oncology
Bremerton, Washington, 98310
Veterans Affairs Medical Center - Buffalo
Buffalo, New York, 14215
Lahey Clinic Medical Center - Burlington
Burlington, Massachusetts, 01805
Alamance Cancer Center at Alamance Regional Medical Center
Burlington, North Carolina, 27216
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
St. James Healthcare Cancer Care
Butte, Montana, 59701
Graham Hospital
Canton, Illinois, 61520
Illinois CancerCare - Canton
Canton, Illinois, 61520
Mercy Cancer Center at Mercy Medical Center
Canton, Ohio, 44708
Aultman Cancer Center at Aultman Hospital
Canton, Ohio, 44710-1799
Southeast Cancer Center
Cape Girardeau, Missouri, 63703
Illinois CancerCare - Carthage
Carthage, Illinois, 62321
Memorial Hospital
Carthage, Illinois, 62321
Rocky Mountain Oncology
Casper, Wyoming, 82609
East Bay Radiation Oncology Center
Castro Valley, California, 94546
Valley Medical Oncology Consultants - Castro Valley
Castro Valley, California, 94546
Sandra L. Maxwell Cancer Center
Cedar City, Utah, 84720
Cedar Rapids Oncology Associates
Cedar Rapids, Iowa, 52403
Mercy Regional Cancer Center at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Providence Centralia Hospital
Centralia, Washington, 98531-9027
Cancer Center of Kansas, PA - Chanute
Chanute, Kansas, 66720
Roper St. Francis Cancer Center at Roper Hospital
Charleston, South Carolina, 29401
Hollings Cancer Center at Medical University of South Carolina
Charleston, South Carolina, 29425
Blumenthal Cancer Center at Carolinas Medical Center
Charlotte, North Carolina, 28232-2861
Saint Luke's Hospital
Chesterfield, Missouri, 63017
Mount Sinai Hospital Medical Center
Chicago, Illinois, 60608
Resurrection Medical Center
Chicago, Illinois, 60631
Louis A. Weiss Memorial Hospital
Chicago, Illinois, 60640
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Christ Hospital Cancer Center
Cincinnati, Ohio, 45219
Charles M. Barrett Cancer Center at University Hospital
Cincinnati, Ohio, 45267
Clackamas Radiation Oncology Center
Clackamas, Oregon, 97015
United Hospital Center
Clarksburg, West Virginia, 26301
Medical Oncology and Hematology Associates - West Des Moines
Clive, Iowa, 50325
Mercy Cancer Center - West Lakes
Clive, Iowa, 50325
Penrose Cancer Center at Penrose Hospital
Colorado Springs, Colorado, 80933
John B. Amos Cancer Center
Columbus, Georgia, 31904
Riverside Methodist Hospital Cancer Care
Columbus, Ohio, 43214-3998
CCOP - Columbus
Columbus, Ohio, 43215
Grant Medical Center Cancer Care
Columbus, Ohio, 43215
Mount Carmel Health - West Hospital
Columbus, Ohio, 43222
Doctors Hospital at Ohio Health
Columbus, Ohio, 43228
New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care
Concord, New Hampshire, 03301
Mercy and Unity Cancer Center at Mercy Hospital
Coon Rapids, Minnesota, 55433
Geisinger Cancer Institute at Geisinger Health
Danville, Pennsylvania, 17822-0001
Mercy Fitzgerald Hospital
Darby, Pennsylvania, 19023
Genesis Regional Cancer Center at Genesis Medical Center
Davenport, Iowa, 52803
Grandview Hospital
Dayton, Ohio, 45405
Good Samaritan Hospital
Dayton, Ohio, 45406
David L. Rike Cancer Center at Miami Valley Hospital
Dayton, Ohio, 45409
Samaritan North Cancer Care Center
Dayton, Ohio, 45415
CCOP - Dayton
Dayton, Ohio, 45420
Oakwood Cancer Center at Oakwood Hospital and Medical Center
Dearborn, Michigan, 48123-2500
Charles B. Eberhart Cancer Center at DeKalb Medical Center
Decatur, Georgia, 30033
Decatur Memorial Hospital Cancer Care Institute
Decatur, Illinois, 62526
Grady Memorial Hospital
Delaware, Ohio, 43015
St. Anthony Central Hospital
Denver, Colorado, 80204
Kaiser Permanente - Denver
Denver, Colorado, 80205
Porter Adventist Hospital
Denver, Colorado, 80210
Presbyterian - St. Luke's Medical Center
Denver, Colorado, 80218
St. Joseph Hospital
Denver, Colorado, 80218
Rose Medical Center
Denver, Colorado, 80220
CCOP - Colorado Cancer Research Program
Denver, Colorado, 80222
CCOP - Iowa Oncology Research Association
Des Moines, Iowa, 50309
John Stoddard Cancer Center at Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates at Mercy Cancer Center
Des Moines, Iowa, 50314
Mercy Cancer Center at Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
John Stoddard Cancer Center at Iowa Lutheran Hospital
Des Moines, Iowa, 50316
Josephine Ford Cancer Center at Henry Ford Hospital
Detroit, Michigan, 48202
Cancer Center of Kansas, PA - Dodge City
Dodge City, Kansas, 67801
Kent General Hospital
Dover, Delaware, 19901
Doylestown Hospital Cancer Center
Doylestown, Pennsylvania, 18901
Delaware County Regional Cancer Center at Delaware County Memorial Hospital
Drexel Hill, Pennsylvania, 19026
Oncology Hematology Associates of Northern Pennsylvania, PC at Hahne Regional Cancer Center
DuBois, Pennsylvania, 15801
Duluth Clinic Cancer Center - Duluth
Duluth, Minnesota, 55805-1983
CCOP - Duluth
Duluth, Minnesota, 55805
Miller - Dwan Medical Center
Duluth, Minnesota, 55805
St. Luke's Hospital Cancer Care Center
Duluth, Minnesota, 55805
Dale and Frances Hughes Cancer Center at Pocono Medical Center
East Stroudsburg, Pennsylvania, 18301
CCOP - Hematology-Oncology Associates of Central New York
East Syracuse, New York, 13057
Shore Regional Cancer Center at Memorial Hospital - Easton
Easton, Maryland, 21601
Fairview Southdale Hospital
Edina, Minnesota, 55435
Cancer Center of Kansas, PA - El Dorado
El Dorado, Kansas, 67042
Sherman Hospital
Elgin, Illinois, 60123
Alexian Brothers Radiation Oncology
Elk Grove Village, Illinois, 60007
Elkhart Clinic, LLC
Elkhart, Indiana, 46514-2098
Michiana Hematology-Oncology, PC - Elkhart
Elkhart, Indiana, 46514
Elkhart General Hospital
Elkhart, Indiana, 46515
Union Hospital of Cecil County
Elkton, Maryland, 21921
Elmhurst Memorial Hospital
Elmhurst, Illinois, 60126
Elmhurst Hospital Center
Elmhurst, New York, 11373
Swedish Medical Center
Englewood, Colorado, 80110
Ephrata Cancer Center at Ephrata Community Hospital
Ephrata, Pennsylvania, 17522
Green Bay Oncology, Limited - Escanaba
Escanaba, Michigan, 49431
Eureka Community Hospital
Eureka, Illinois, 61530
Illinois CancerCare - Eureka
Eureka, Illinois, 61530
Providence Regional Cancer Partnership
Everett, Washington, 98201
Center for Cancer Care at Exeter Hospital
Exeter, New Hampshire, 03833
Kaiser Permanente Medical Center - Fair Oaks
Fairfax, Virginia, 22033
North Bay Cancer Center
Fairfield, California, 94533
Southcoast Center for Cancer Care
Fairhaven, Massachusetts, 02719
Hudner Oncology Center at Saint Anne's Hospital - Fall River
Fall River, Massachusetts, 02721
Dakota Cancer Institute at Dakota Clinic - South University
Fargo, North Dakota, 58103
Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
Farmington, Connecticut, 06360-2875
Piedmont Fayette Hospital
Fayetteville, Georgia, 30214
St. Francis Hospital
Federal Way, Washington, 98003
Blanchard Valley Medical Associates
Findlay, Ohio, 45840
Hunterdon Regional Cancer Center at Hunterdon Medical Center
Flemington, New Jersey, 08822
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Hurley Medical Center
Flint, Michigan, 48503
McLeod Regional Medical Center
Florence, South Carolina, 29501
Kaiser Permanente Medical Center - Fontana
Fontana, California, 92335
Poudre Valley Hospital
Fort Collins, Colorado, 80524
Front Range Cancer Specialists
Fort Collins, Colorado, 80528
Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
Fort Lauderdale, Florida, 33308
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
Fort Smith, Arkansas, 72903
Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Frederick Memorial Hospital Regional Cancer Therapy Center
Frederick, Maryland, 21701
Kaiser Permanente - Fremont
Fremont, California, 94538
Valley Medical Oncology
Fremont, California, 94538
Mercy and Unity Cancer Center at Unity Hospital
Fridley, Minnesota, 55432
Virginia K. Crosson Cancer Center at St. Jude Medical Center
Fullerton, California, 92835
University of Florida Shands Cancer Center
Gainesville, Florida, 32610-0232
Kaiser Permanente - Gaithersburg Medical Center
Gaithersburg, Maryland, 20879
Galesburg Clinic, PC
Galesburg, Illinois, 61401
Illinois CancerCare - Galesburg
Galesburg, Illinois, 61401
Adams Cancer Center
Gettysburg, Pennsylvania, 17325
Glendale Memorial Hospital Comprehensive Cancer Center
Glendale, California, 91204
Wayne Memorial Hospital, Incorporated
Goldsboro, North Carolina, 27534
Altru Cancer Center at Altru Hospital
Grand Forks, North Dakota, 58201
St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
Grand Junction, Colorado, 81502
Butterworth Hospital at Spectrum Health
Grand Rapids, Michigan, 49503
CCOP - Grand Rapids
Grand Rapids, Michigan, 49503
Lacks Cancer Center at Saint Mary's Health Care
Grand Rapids, Michigan, 49503
Big Sky Oncology
Great Falls, Montana, 59405-5309
Great Falls Clinic - Main Facility
Great Falls, Montana, 59405
Sletten Cancer Institute at Benefis Healthcare
Great Falls, Montana, 59405
North Colorado Medical Center
Greeley, Colorado, 80631
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54301-3526
Bellin Memorial Hospital
Green Bay, Wisconsin, 54301
Green Bay Oncology, Limited at St. Mary's Hospital
Green Bay, Wisconsin, 54303
St. Mary's Hospital Medical Center - Green Bay
Green Bay, Wisconsin, 54303
St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54307-3508
Moses Cone Regional Cancer Center at Wesley Long Community Hospital
Greensboro, North Carolina, 27403-1198
Wayne Hospital
Greenville, Ohio, 45331
Bon Secours St. Francis Health System
Greenville, South Carolina, 29601
Cancer Centers of the Carolinas - Faris Road
Greenville, South Carolina, 29605
Cancer Centers of the Carolinas - Grove Commons
Greenville, South Carolina, 29605
Greenville Hospital Cancer Center
Greenville, South Carolina, 29605
CCOP - Greenville
Greenville, South Carolina, 29615
Bendheim Cancer Center at Greenwich Hospital
Greenwich, Connecticut, 06830
Cancer Centers of the Carolinas - Greer Medical Oncology
Greer, South Carolina, 29650
Van Elslander Cancer Center at St. John Hospital and Medical Center
Grosse Pointe Woods, Michigan, 48236
CCOP - Northern New Jersey
Hackensack, New Jersey, 07601
Cherry Tree Cancer Center
Hanover, Pennsylvania, 17331
Kaiser Permanente Medical Center - Harbor City
Harbor City, California, 90710
PinnacleHealth Regional Cancer Center at Polyclinic Hospital
Harrisburg, Pennsylvania, 17110-2098
Helen and Harry Gray Cancer Center at Hartford Hospital
Hartford, Connecticut, 06102-5037
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
Hartford, Connecticut, 06105
Ingalls Cancer Care Center at Ingalls Memorial Hospital
Harvey, Illinois, 60426
Illinois CancerCare - Havana
Havana, Illinois, 62644
Mason District Hospital
Havana, Illinois, 62644
Kaiser Permanente Medical Center - Hayward
Hayward, California, 94545
Geisinger Hazleton Cancer Center
Hazleton, Pennsylvania, 18201
St. Peter's Hospital
Helena, Montana, 59601
Pardee Memorial Hospital
Hendersonville, North Carolina, 28791
Hinsdale Hematology Oncology Associates
Hinsdale, Illinois, 60521
Cancer Research Center of Hawaii
Honolulu, Hawaii, 96813
OnCare Hawaii, Incorporated - Lusitana
Honolulu, Hawaii, 96813
Queen's Cancer Institute at Queen's Medical Center
Honolulu, Hawaii, 96813
Straub Clinic and Hospital, Incorporated
Honolulu, Hawaii, 96813
OnCare Hawaii, Incorporated - Kuakini
Honolulu, Hawaii, 96817
Kaiser Permanente - Moanalua Medical Center and Clinic
Honolulu, Hawaii, 96819
Tripler Army Medical Center
Honolulu, Hawaii, 96859
New Hampshire Oncology - Hematology, PA - Hooksett
Hooksett, New Hampshire, 03106
M. D. Anderson Cancer Center at University of Texas
Houston, Texas, 77030-4009
St. Mary's Regional Cancer Center at St. Mary's Medical Center
Huntington, West Virginia, 25702
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
St. Vincent Indianapolis Hospital
Indianapolis, Indiana, 46260
Holden Comprehensive Cancer Center at University of Iowa
Iowa City, Iowa, 52242-1002
Dickinson County Healthcare System
Iron Mountain, Michigan, 49801
Kaiser Permanente - Irvine
Irvine, California, 92618
Foote Memorial Hospital
Jackson, Michigan, 49201
St. Vincent's Medical Center
Jacksonville, Florida, 32204
Baptist Cancer Institute - Jacksonville
Jacksonville, Florida, 32207
Queens Cancer Center of Queens Hospital
Jamaica, New York, 11432
Mercy Regional Cancer Center
Janesville, Wisconsin, 53547
Goldschmidt Cancer Center
Jefferson City, Missouri, 65109
Joliet Oncology-Hematology Associates, Limited - West
Joliet, Illinois, 60435
Ella Milbank Foshay Cancer Center at Jupiter Medical Center
Jupiter, Florida, 33458
Borgess Medical Center
Kalamazoo, Michigan, 49001
West Michigan Cancer Center
Kalamazoo, Michigan, 49007-3731
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
Glacier Oncology, PLLC
Kalispell, Montana, 59901
Kalispell Medical Oncology at KRMC
Kalispell, Montana, 59901
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Saint Luke's Cancer Institute at Saint Luke's Hospital
Kansas City, Missouri, 64111
North Kansas City Hospital
Kansas City, Missouri, 64116
Heartland Hematology Oncology Associates, Incorporated
Kansas City, Missouri, 64118
Research Medical Center
Kansas City, Missouri, 64132
Charles F. Kettering Memorial Hospital
Kettering, Ohio, 45429
Illinois CancerCare - Kewanee Clinic
Kewanee, Illinois, 61443
Cancer Center of Kansas, PA - Kingman
Kingman, Kansas, 67068
Christine LaGuardia Phillips Cancer Center at Wellmont Holston Valley Medical Center
Kingsport, Tennessee, 37662
Kinston Medical Specialists
Kinston, North Carolina, 28501
Thompson Cancer Survival Center
Knoxville, Tennessee, 37916
Howard Community Hospital
Kokomo, Indiana, 46904
La Grange Memorial Hospital
La Grange, Illinois, 60525
Center for Cancer Therapy at LaPorte Hospital and Health Services
La Porte, Indiana, 46350
Lakes Region General Hospital
Laconia, New Hampshire, 03246
Kaiser Permanente - Lafayette
Lafayette, Colorado, 80026
Monter Cancer Center of the North Shore-LIJ Health System
Lake Success, New York, 11042
Fairfield Medical Center
Lancaster, Ohio, 43130
Breslin Cancer Center at Ingham Regional Medical Center
Lansing, Michigan, 48910
Sparrow Regional Cancer Center
Lansing, Michigan, 48912-1811
Doctor's Hospital of Laredo
Laredo, Texas, 78045
Kaiser Permanente Mid-Atlantic Medical Group-Largo Medical Facility
Largo, Maryland, 20774
University Medical Center of Southern Nevada
Las Vegas, Nevada, 89102
CCOP - Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Gwinnett Medical Center
Lawrenceville, Georgia, 30045
Saint Luke's East - Lee's Summit
Lee's Summit, Missouri, 64086
Tunnell Cancer Center at Beebe Medical Center
Lewes, Delaware, 19958
St. Joseph Regional Medical Center
Lewiston, Idaho, 83501
Central Baptist Hospital
Lexington, Kentucky, 40503-9985
Cancer Center of Kansas, PA - Liberal
Liberal, Kansas, 67901
Parvin Radiation Oncology
Liberty, Missouri, 64068
St. Rita's Medical Center
Lima, Ohio, 45801
Cancer Resource Center - Lincoln
Lincoln, Nebraska, 68510
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
Study site
Little Rock, Arkansas, 72205
Littleton Adventist Hospital
Littleton, Colorado, 80122
St. Barnabas Medical Center Cancer Center
Livingston, New Jersey, 07039
St. Mary Mercy Hospital
Livonia, Michigan, 48154
Logan Regional Hospital
Logan, Utah, 84321
Sky Ridge Medical Center
Lone Tree, Colorado, 80124
Canada3 sites
Cancer Centre of Southeastern Ontario at Kingston General Hospital
Kingston, Ontario, K7L 5P9
Royal Victoria Hospital - Montreal
Montreal, Quebec, H3A 1A1
Hopital du Saint-Sacrement - Quebec
Québec, Quebec, G1S 4L8
About this study
Official title: Statin Polyp Prevention Trial in Patients With Resected Colon Cancer
RATIONALE: Rosuvastatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving rosuvastatin after surgery may kill any tumor cells that remain after surgery. It may also keep polyps from forming or colon cancer from coming back. It is not yet known whether rosuvastatin is more effective than a placebo in treating colon cancer that was removed by surgery.
PURPOSE: This randomized phase III trial is studying rosuvastatin to see how well it works compared with placebo in treating patients with stage I or stage II colon cancer that was removed by surgery.
Read the detailed description
OBJECTIVES:
Primary
- To compare the effect of rosuvastatin vs placebo on the 5-year occurrence of adenomatous polyps of the colon or rectum, metachronous colorectal carcinoma, or colon cancer recurrence (APMC+R) in patients with resected stage I or II colon cancer.
Secondary
- To determine whether the effect of rosuvastatin vs placebo is of the same magnitude in patients taking aspirin (regardless of dose) compared to patients not taking aspirin.
- To determine whether taking aspirin (regardless of dose) vs no aspirin will decrease the occurrence or APMC+R and, if there is an effect, to explore the relationship to dose.
- To determine the effect of rosuvastatin in patients with familial colorectal cancer.
- To determine the effect of rosuvastatin in patients with microsatellite unstable tumors (i.e., tumors displaying loss of MLH1 or MSH2 expression by IHC).
- To determine the relationship between rosuvastatin therapy and features of colorectal adenomas as well as the size and number of colorectal adenomas.
- To compare the time to APMC+R in patients treated with rosuvastatin vs placebo.
- To compare the disease-free survival of patients treated with rosuvastatin vs placebo.
- To compare the overall survival of patients treated with rosuvastatin vs placebo.
- To compare the rate of recurrence of colon cancer in patients treated with rosuvastatin vs placebo.
- To compare the rate of second non-colorectal primary cancers in patients treated with rosuvastatin vs placebo.
- To determine the effect of rosuvastatin on health-related quality of life, global quality of life, and self-reported symptoms.
- To compare the incidence and severity of adverse events associated with rosuvastatin vs placebo.
- To assess relevant tumor and blood markers that may affect the metabolism, activity, or effect of the study drugs, such as HMG-CoA reductase, UGT1A6, P450-2C9, PTGS2 (COX-2), and other possible markers.
OUTLINE: This is a multicenter study. Patients are stratified according to family history of a first-degree relative with colorectal cancer (yes vs no), intended aspirin dose (none vs 81 mg vs 325 mg), and adjuvant therapy for colon cancer (yes vs no). Patients are randomized to 1 of 2 treatment arms.
- Group 1: Patients receive oral placebo once daily for 5 years.
- Group 2: Patients receive oral rosuvastatin once daily for 5 years.
Patients may complete a quality-of-life questionnaire at baseline and at 6, 12, 36, 60, and 84 months.
Tumor tissue, serum, and blood samples may be collected periodically for biomarker and other analyses.
After completion of study treatment, patients are followed up periodically for up to 2 years.
- Conditions
- Colorectal Cancer, Precancerous Condition
- Being tested
- rosuvastatin, placebo
- Keywords
- adenomatous polyp, stage I colon cancer, stage II colon cancer, adenocarcinoma of the colon
- Medical subject headings
- Colorectal Neoplasms, Precancerous Conditions, Adenomatous Polyps, Colonic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
rosuvastatinDrug
Also called Crestor
placeboOther
| Study group | Role | What they receive |
|---|---|---|
| Group 1: placebo | Placebo comparator | Patients receive oral placebo once daily for 5 years. Receives: Other: placebo |
| Group 2: rosuvastatin | Experimental | Patients receive oral rosuvastatin once daily for 5 years. Receives: Drug: rosuvastatin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Occurrence of ≥ 1 Adenomatous Polyp of the Colon or Rectum, Metachronous Colorectal Carcinoma, or Colon Cancer Recurrence (APMC+R)
Percentage of patients with occurrence of APMC+R event. APMC+R events include at least one adenomatous polyp of the colon or rectum, metachronous colorectal carcinoma, or colon cancer recurrence
Measured: Up to 4.8 years
Secondary outcomes (8)
Size of Colorectal Adenomas, Including Advanced Adenomas
The histologic size (diameter of adenoma into the wall of the colon; as per AJCC staging) of the largest adenoma among patients who have at least one adenoma detected. If histologic size was not available, the endoscopic size was provided.
Measured: Up to 4.8 years
Disease-free Survival
Number of patients with DFS event (colon cancer recurrence, second primary cancer, or death from any cause)
Measured: Up to 4.8 years
Overall Survival (OS)
Number of patients with the OS event (death from any cause)
Measured: Up to 4.8 years
Recurrence-free Interval (RFI)
Number of patients with the RFI event (First recurrence of colon cancer)
Measured: Up to 4.8 years
Second Non-colorectal Primary Cancer-free Interval
Number of patients with the first occurrence of non-colorectal primary cancer
Measured: Up to 4.8 years
Behavioral and Health Outcomes as Measured by SF-12 Component Scores, Global Quality-of-life Scale, and Symptom Checklist
Global Quality-of-life Scale score, ranges from 0 (worst imaginable health status) to 10 (best imaginable health status.
Measured: 12-month time point
Toxicity Assessed by Adverse Events
Percentage of patients with at least one grade 2 or higher adverse event reported.
Measured: Up to 4.8 years
Measurements of Relevant Tumor and Blood Markers
This study terminated early. Data on samples was not collected, the relevant analyses were not performed.
Measured: At randomization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Nov 2009 (estimated)
- Study startMar 2010
- Primary completionDec 2014
- Study completionFeb 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Colorectal CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 406 participants (actual)
Sponsor and investigators
- Lead sponsor
- NSABP Foundation Inc
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Norman Wolmark, MD, Principal investigator, NSABP Foundation Inc
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01011478
- Sponsor's protocol ID
- NSABP-P-5
- Other IDs
- NSABP P-5, NCI-2011-09183
- Status last verified
- Jul 2023
- First submitted
- 10 Nov 2009
- Last updated
- 16 Aug 2023
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Boman BM, Bandos H, Wickerham DL, et al.: Statin polyp prevention trial in patients with resected colon cancer: NSABP protocol P-5. [Abstract] J Clin Oncol 30 (Suppl 15): A-TPS1615, 2012.
Study at a glance
From the registry record, last updated by the sponsor on 16 Aug 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Statin Polyp Prevention Trial in Patients With Resected Colon Cancer
- ClinicalTrials.gov ID
- NCT01011478
- Acronym / sponsor ID
- NSABP-P-5
- Conditions
- Colorectal Cancer, Precancerous Condition
- Keywords
- adenomatous polyp, stage I colon cancer, stage II colon cancer, adenocarcinoma of the colon
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Terminated
- Enrolment
- 406 participants (actual)
- Lead sponsor
- NSABP Foundation IncResearch network
- Collaborators
- National Cancer Institute (NCI)
- Study start
- Mar 2010
- Primary completion
- Dec 2014 (actual)
- Study completion
- Feb 2015 (actual)
- First posted
- 11 Nov 2009 (estimated)
- Results
- Posted 16 Aug 2023
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Rosuvastatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving rosuvastatin after surgery may kill any tumor cells that remain after surgery. It may also keep polyps from forming or colon cancer from coming back. It is not yet known whether rosuvastatin is more effective than a placebo in treating colon cancer that was removed by surgery.
PURPOSE: This randomized phase III trial is studying rosuvastatin to see how well it works compared with placebo in treating patients with stage I or stage II colon cancer that was removed by surgery.
Detailed description
OBJECTIVES:
Primary
- To compare the effect of rosuvastatin vs placebo on the 5-year occurrence of adenomatous polyps of the colon or rectum, metachronous colorectal carcinoma, or colon cancer recurrence (APMC+R) in patients with resected stage I or II colon cancer.
Secondary
- To determine whether the effect of rosuvastatin vs placebo is of the same magnitude in patients taking aspirin (regardless of dose) compared to patients not taking aspirin.
- To determine whether taking aspirin (regardless of dose) vs no aspirin will decrease the occurrence or APMC+R and, if there is an effect, to explore the relationship to dose.
- To determine the effect of rosuvastatin in patients with familial colorectal cancer.
- To determine the effect of rosuvastatin in patients with microsatellite unstable tumors (i.e., tumors displaying loss of MLH1 or MSH2 expression by IHC).
- To determine the relationship between rosuvastatin therapy and features of colorectal adenomas as well as the size and number of colorectal adenomas.
- To compare the time to APMC+R in patients treated with rosuvastatin vs placebo.
- To compare the disease-free survival of patients treated with rosuvastatin vs placebo.
- To compare the overall survival of patients treated with rosuvastatin vs placebo.
- To compare the rate of recurrence of colon cancer in patients treated with rosuvastatin vs placebo.
- To compare the rate of second non-colorectal primary cancers in patients treated with rosuvastatin vs placebo.
- To determine the effect of rosuvastatin on health-related quality of life, global quality of life, and self-reported symptoms.
- To compare the incidence and severity of adverse events associated with rosuvastatin vs placebo.
- To assess relevant tumor and blood markers that may affect the metabolism, activity, or effect of the study drugs, such as HMG-CoA reductase, UGT1A6, P450-2C9, PTGS2 (COX-2), and other possible markers.
OUTLINE: This is a multicenter study. Patients are stratified according to family history of a first-degree relative with colorectal cancer (yes vs no), intended aspirin dose (none vs 81 mg vs 325 mg), and adjuvant therapy for colon cancer (yes vs no). Patients are randomized to 1 of 2 treatment arms.
- Group 1: Patients receive oral placebo once daily for 5 years.
- Group 2: Patients receive oral rosuvastatin once daily for 5 years.
Patients may complete a quality-of-life questionnaire at baseline and at 6, 12, 36, 60, and 84 months.
Tumor tissue, serum, and blood samples may be collected periodically for biomarker and other analyses.
After completion of study treatment, patients are followed up periodically for up to 2 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group 1: placebo | Placebo comparator | Other: placeboPatients receive oral placebo once daily for 5 years. |
| Group 2: rosuvastatin | Experimental | Drug: rosuvastatinPatients receive oral rosuvastatin once daily for 5 years. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Patients must have the ability to swallow oral medication.
- Patients must have resected adenocarcinoma of the colon staged as American Joint Committee on Cancer (AJCC) Stage 0, I, II, or III.
- Patients must have had surgical resection of the colon adenocarcinoma with curative intent within 1 year prior to randomization. (Laparoscopically-assisted colectomy is permitted.)
- Patients must have completed any adjuvant therapy prior to randomization.
Key exclusion criteria (17 listed)
- Tumor with the distal border located less than 12 cm from the anal verge.
- Total colectomy or total proctocolectomy.
- Classic Familial Adenomatous Polyposis, Attenuated Familial Adenomatous Polyposis (i.e., 20 or more adenomas, either synchronous or metachronous), or Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome).
- Malabsorption syndrome, ulcerative colitis, inflammatory bowel disease, resection of the stomach or small bowel, or other disease significantly affecting gastrointestinal function.
- History of documented upper GI bleeding or upper GI ulcerative disease.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| rosuvastatinAlso: Crestor | Drug | Group 2: rosuvastatin |
| placebo | Other | Group 1: placebo |
Primary outcome
Occurrence of ≥ 1 Adenomatous Polyp of the Colon or Rectum, Metachronous Colorectal Carcinoma, or Colon Cancer Recurrence (APMC+R)
Time frame: Up to 4.8 years
Percentage of patients with occurrence of APMC+R event. APMC+R events include at least one adenomatous polyp of the colon or rectum, metachronous colorectal carcinoma, or colon cancer recurrence
8 secondary outcomes
Size of Colorectal Adenomas, Including Advanced Adenomas
Time frame: Up to 4.8 years
Disease-free Survival
Time frame: Up to 4.8 years
Overall Survival (OS)
Time frame: Up to 4.8 years
Recurrence-free Interval (RFI)
Time frame: Up to 4.8 years
Second Non-colorectal Primary Cancer-free Interval
Time frame: Up to 4.8 years
Behavioral and Health Outcomes as Measured by SF-12 Component Scores, Global Quality-of-life Scale, and Symptom Checklist
Time frame: 12-month time point
Toxicity Assessed by Adverse Events
Time frame: Up to 4.8 years
Measurements of Relevant Tumor and Blood Markers
Time frame: At randomization
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Aug 2023.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publicationBoman BM, Bandos H, Wickerham DL, et al.: Statin polyp prevention trial in patients with resected colon cancer: NSABP protocol P-5. [Abstract] J Clin Oncol 30 (Suppl 15): A-TPS1615, 2012.
Related trials for Colorectal Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingObservational study
Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer
Rectal Neoplasms
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Norman Wolmark, MD principal investigator
NSABP Foundation Inc
587 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing rosuvastatin in people with Colorectal Cancer and Precancerous Condition, run by NSABP Foundation Inc at 587 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 16 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 587 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 16 Aug 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Occurrence of ≥ 1 Adenomatous Polyp of the Colon or Rectum, Metachronous Colorectal Carcinoma, or Colon Cancer Recurrence (APMC+R) (time frame: Up to 4.8 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01011478, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Aug 2023.